OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
Ming Dai, Feng Yin, Shang Wen Chen, et al.
Breast Cancer Research and Treatment (2021) Vol. 189, Iss. 3, pp. 665-676
Open Access | Times Cited: 19
Ming Dai, Feng Yin, Shang Wen Chen, et al.
Breast Cancer Research and Treatment (2021) Vol. 189, Iss. 3, pp. 665-676
Open Access | Times Cited: 19
Showing 19 citing articles:
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 270
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 270
Emerging Targeted Therapies for HER2-Positive Breast Cancer
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 81
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 81
Neratinib for HER2-positive breast cancer with an overlooked option
Liting Guo, Weiwei Shao, Chenfei Zhou, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 22
Liting Guo, Weiwei Shao, Chenfei Zhou, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 22
Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
Nicki M. Kyriacou, Annette S. Gross, Andrew J. McLachlan
Clinical and Translational Science (2025) Vol. 18, Iss. 5
Open Access
Nicki M. Kyriacou, Annette S. Gross, Andrew J. McLachlan
Clinical and Translational Science (2025) Vol. 18, Iss. 5
Open Access
Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
Desh Deepak Singh, Hae‐Jeung Lee, Dharmendra Kumar Yadav
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 15
Desh Deepak Singh, Hae‐Jeung Lee, Dharmendra Kumar Yadav
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 15
Drug repurposing for Basal breast cancer subpopulations using modular network signatures
Hiram Coria-Rodríguez, Soledad Ochoa, Guillermo de Anda‐Jáuregui, et al.
Computational Biology and Chemistry (2023) Vol. 105, pp. 107902-107902
Closed Access | Times Cited: 8
Hiram Coria-Rodríguez, Soledad Ochoa, Guillermo de Anda‐Jáuregui, et al.
Computational Biology and Chemistry (2023) Vol. 105, pp. 107902-107902
Closed Access | Times Cited: 8
The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
Zihong Wu, Jiamei Wang, Feng-Ming You, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Zihong Wu, Jiamei Wang, Feng-Ming You, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Reporting of older subgroups in registration breast cancer trials 2012–2021
Colm Mac Eochagáin, Nicolò Matteo Luca Battisti
Breast Cancer Research and Treatment (2023) Vol. 202, Iss. 3, pp. 411-421
Closed Access | Times Cited: 5
Colm Mac Eochagáin, Nicolò Matteo Luca Battisti
Breast Cancer Research and Treatment (2023) Vol. 202, Iss. 3, pp. 411-421
Closed Access | Times Cited: 5
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
Aya Abunada, Zaid Sirhan, Anita Thyagarajan, et al.
World Journal of Clinical Oncology (2023) Vol. 14, Iss. 5, pp. 198-202
Open Access | Times Cited: 4
Aya Abunada, Zaid Sirhan, Anita Thyagarajan, et al.
World Journal of Clinical Oncology (2023) Vol. 14, Iss. 5, pp. 198-202
Open Access | Times Cited: 4
Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs
M. Ayub, A Tyagi, Sunil K. Srivastava, et al.
Journal of Materials Chemistry B (2024) Vol. 13, Iss. 1, pp. 218-238
Closed Access | Times Cited: 1
M. Ayub, A Tyagi, Sunil K. Srivastava, et al.
Journal of Materials Chemistry B (2024) Vol. 13, Iss. 1, pp. 218-238
Closed Access | Times Cited: 1
Metastatic brain tumors: from development to cutting‐edge treatment
Guilong Tanzhu, Liu Chen, Jiaoyang Ning, et al.
MedComm (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Guilong Tanzhu, Liu Chen, Jiaoyang Ning, et al.
MedComm (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
A comprehensive clinical evaluation of HER2-TKIs in patients with previously treated HER2-positive metastatic breast cancer
Wenjun Ji, Xuan Lu, Yugang Wang, et al.
Anti-Cancer Drugs (2024)
Closed Access | Times Cited: 1
Wenjun Ji, Xuan Lu, Yugang Wang, et al.
Anti-Cancer Drugs (2024)
Closed Access | Times Cited: 1
INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib
Na Qu, Gang Wang, Yue Su, et al.
Biochemical Pharmacology (2024) Vol. 226, pp. 116347-116347
Closed Access | Times Cited: 1
Na Qu, Gang Wang, Yue Su, et al.
Biochemical Pharmacology (2024) Vol. 226, pp. 116347-116347
Closed Access | Times Cited: 1
Advances from targeted therapy for non‐metastatic HER2‐positive inflammatory breast cancer
Jessica A. Steadman, Tina J. Hieken
Journal of Surgical Oncology (2024) Vol. 130, Iss. 3, pp. 366-370
Closed Access | Times Cited: 1
Jessica A. Steadman, Tina J. Hieken
Journal of Surgical Oncology (2024) Vol. 130, Iss. 3, pp. 366-370
Closed Access | Times Cited: 1
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
Yuwen Bao, Zhuolin Zhang, Xuan He, et al.
Current Oncology (2022) Vol. 29, Iss. 9, pp. 6053-6067
Open Access | Times Cited: 6
Yuwen Bao, Zhuolin Zhang, Xuan He, et al.
Current Oncology (2022) Vol. 29, Iss. 9, pp. 6053-6067
Open Access | Times Cited: 6
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5499-5499
Open Access | Times Cited: 3
María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5499-5499
Open Access | Times Cited: 3
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
Lanqi Ren, Ning Ren, Yu Zheng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Lanqi Ren, Ning Ren, Yu Zheng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Phosphoproteomic analysis reveals the diversity of signaling behind ErbB inhibitor-induced phenotypes
Katri Vaparanta, Anne Jokilammi, Johannes Merilahti, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Katri Vaparanta, Anne Jokilammi, Johannes Merilahti, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Cost-effectiveness analysis of neratinib plus capecitabine against lapatinib plus capecitabine for HER2-Positive metastatic breast cancer
Jiangbo Shao, Yu He, Cuiping Zhan, et al.
Research Square (Research Square) (2022)
Open Access
Jiangbo Shao, Yu He, Cuiping Zhan, et al.
Research Square (Research Square) (2022)
Open Access
